Ivan Šnajdr

All publications

Latest publications

Discovery of tert-Butyl Ester Based 6-Diazo-5-oxo-L-norleucine Prodrugs for Enhanced Metabolic Stability and Tumor Delivery

K. Novotná L. Tenora E. Prchalová J. Paule J. Alt V. Veeravalli J. Lam Y. Wu I. Šnajdr S. Gori V. S. Mettu T. Tsukamoto P. Majer B. S. Slusher R. Rais

Journal of Medicinal Chemistry 66 (22): 15493–15510 (2023)

A gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis

D. E. Peters L. D. Norris L. Tenora I. Šnajdr A. K. Ponti X. Zhu S. Sakamoto V. Veeravalli M. Pradhan J. Alt A. G. Thomas M. Majer R. Rais C. McDonald B. S. Slusher

Science Translational Medicine 15 (708): eabn7491 (2023)

Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6)

L. Motlová I. Šnajdr Z. Kutil E. Andris J. Ptáček A. Novotná Z. Nováková B. Havlínová W. Tueckmantel H. Dráberová P. Majer M. Schutkowski A. Kozikowski L. Rulíšek C. Bařinka

ACS Chemical Biology 18 (7): 1594–1610 (2023)

Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells

J. Ptáček I. Šnajdr J. Schimer Z. Kutil J. Mikešová P. Baranová B. Havlínová W. Tueckmantel P. Majer A. Kozikowski C. Bařinka

International Journal of Molecular Sciences 24 (5): 4720 (2023)